CORDIS - Résultats de la recherche de l’UE

Synchrotron Miniaturization enabling Innovative Laboratory Equipment in soft x-ray tomography.


The aim of SMILE is to support SiriusXT in moving a prototype of its soft x-ray microscope (SXT100) from prototype to commercial product through addressing ease-of-assembly, manufacturing scale-up, serviceability, customer pilots, regulatory pathways and business model requirements.
The disruptive innovation delivered by SMILE is to open up the market for soft x-ray imaging from approx. 100 users today to an immediate target addressable market of over 3,000 disease research and drug discovery organisations by reducing the cost of the microscope assembly by a factor of over 200 (from over €500 million to €2.5 million) and miniaturizing its size, by a factor of 5,000 (from 15,000m2 area to approx. 3m2).
Soft x-ray imaging is the only means available today of generating high resolution, high contrast, 3D images of the internal structure of whole biological cells in their near-natural state. Cell researchers currently spend approx. €500m annually on electron and optical microscopes in order to increase their understanding of subcellular structure and how this relates to disease progression and therapy, however neither of these technologies is capable of imaging the whole internal cell structure.
The SXT100 gives disease research and drug discovery organisations daily access to a soft x-ray microscope in their own labs, rather than having to queue for often more than six months to get a few hours of access to one of only four synchrotron locations around the world where a suitable soft x-ray source and microscope exists today. The SXT100 will not only increase a researcher’s productivity 100-fold, in the number of biological cells they can image, but it also allows them to carry out a range of disease progression studies, not possible today because of the restricted access to these synchrotron microscopes.
SMILE is predicted to have a significant impact in addressing the EU/global challenge in reducing the cost of healthcare delivery and developing cures for disease.

Appel à propositions


Voir d’autres projets de cet appel

Sous appel


Régime de financement

SME-2 - SME instrument phase 2


Contribution nette de l'UE
€ 3 000 935,00
A96 XV67 Dublin

Voir sur la carte


L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.

Ireland Eastern and Midland Dublin
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Coût total
€ 3 000 935,00